Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

OPAL: "Opiates and PhArmacoLogy" (OPAL)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2016 by Nantes University Hospital
Information provided by (Responsible Party):
Nantes University Hospital Identifier:
First received: April 10, 2013
Last updated: March 24, 2016
Last verified: March 2016

The aim of this study is to determine the current prevalence of co-addictions, including problem/pathological gambling, in patients receiving Opiate Substitution Treatment (OST), and to then compare patients receiving OST with or without a co-addiction (excluding tobacco dependence) in order to determine their clinical profile.

In addition, an ancillary study to be carried out only among those patients receiving methadone, will aim to etablish whether a low plasma concentration of methadone, on the one hand, and an ultrarapid metabolizer genetic profile, on the other, are the characteristics most commonly associated with the presence of co-addictions. This will allow us to complete patient's pharmacological characterization.

Substance Use Disorder

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Multicenter Study Assessing the Prevalence of Co-addictions in Subjects Receiving Maintenance Treatment for Opiate Dependence. Determination of Clinical and Pharmacological Profil.

Further study details as provided by Nantes University Hospital:

Primary Outcome Measures:
  • Presence or absence of co-addictions (exept tobacco dependence) [ Time Frame: 1 day ]

Biospecimen Retention:   Samples With DNA
Collecting 2 EDTA tubes of 5 mL (blood)

Estimated Enrollment: 354
Study Start Date: January 2014
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Patients on OST prescribed to treat opiate dependence
Collecting socio-demographic data, data concerning opiate dependence, data about other substance use disorder, data regarding gambling practice, psychopathological data.

Detailed Description:

Non-interventionel study Total duration: 12 months (preparation, recruitment, analysis) Recruitment period: 6 months Duration of monitoring per patient: no monitoring

Main objective: to assess the current prevalence of addictive co-morbidities in opiate-dependent subjects receiving Opiate Substitution Treatment (OST) for at least 6 months.

Secondary objective: to compare patients being treated using OST who currently have a co-addiction (with the exception of tobacco dependence) with patients being treated with OST who do not currently have a co-addiction, based on pharmacological and clinical characteristics (for pharmacological characteristics: pharmacokinetic and pharmacogenetic analyses as part of an ancillary study into only those patients being treated with methadone).

Main judgment criterion: Presence or absence of co-addictions (except tobacco dependence), determined using assessment tools.

The secondary assessment criteria shall be: sociodemographic data, data about opiate dependence, data about other substance use disorders, data about gambling practice, psychopathological data (impulsivity, ADHD), pharmacokinetic data and pharmacogenetic data.

Statistical analysis: For the main judgment criterion, a rate of prevalence of current co-addictions will be estimated using a 95% confidence interval.

Descriptive analyses will be carried out for all variables gathered and along with point estimates and 95% confidence intervals for qualitative and quantitative variables.

The second stage will involve univariate exploratory analyses. The two groups of patients will be compared according to the presence or absence of co-addictions. For the quantitative variables Student tests or non parametric tests will be used. For the qualitative variables, we will use Chi-squared or Fisher tests.

Finally, multivariate analyses will be carried out. The factors that have been previously identified as a being linked to co-addictions (with the threshold p = 0.2) will the be incorporated into logistic regression models. The best model, wich enables explanation of the co-addictions will then be selected using likelihood ratio tests.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The study deals with patients on OST precsribed to treat opiate dependence; the OST may be methadone, buprenorphine (+/- naloxone) or a morphine-based drug.

The total group of patients to be inclued is estimated at 384 patients. Of these patients, 200 will take part in the ancillary study.

The number of recruitment centers foreseen allows this objective to be met in 6 months.

Those participating in this study will not be able to participate in another study (notably in order to avoid drug interactions).


General Inclusion Criteria:

  • Over 18,
  • Under treatment unsing methadone or buprenorhine (+/- naloxone) or morphine as substitute, prescribed for opiate dependence,
  • OST begining at least 6 months previously,
  • Incarceration for less than a month in the event of monitoring in SMPR,
  • Good understanding of French, able to read and write.

General non-Inclusion Criteria:

  • Protected adults (guardianship, wardship)
  • Disorder of higher-order brains functions (severe cognitive disorders or confusion) or psychotic disorder (hallucinations, delusion) that may interfere with the study.

Non-Inclusion criteria for patients participating in the ancillary study:

  • Medical monitoring by a doctor from the Drug Addiction Network of the Nantes Area,
  • OST other than methadone
  • Adjustement to dosage in the 5 days prior to administering OST
  • Pregnant women
  • Absence of social security registration.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01847729

Contact: Marie GRALL-BRONNEC, Doctor

Brest Universit Hospital Recruiting
Brest, France, 29820
Contact: Pierre Bodenez, Dr   
Principal Investigator: Pierre Bodenez, Dr         
CSAPA "La métairie" Terminated
La Roche sur Yon, France, 85000
Morlaix Hospital Terminated
Morlaix, France, 29672
CSAPA "Le triangle" Recruiting
Nantes, France, 44000
Contact: Paul Bolo, Dr   
Principal Investigator: Paul Bolo, Dr         
University Hospital Nantes Recruiting
Nantes, France, 44093
Contact: Marie Grall-Bronnec, Doctor    02 40 84 61 16   
Principal Investigator: Marie Grall-Bronnec, Doctor         
CSAPA-CAARUD "La rose des vents" Terminated
Saint Nazaire, France, 44600
Réseau toxicomanie de la région nantaise Terminated
Sébastien sur Loire, France, 44230
Sponsors and Collaborators
Nantes University Hospital
Study Director: Marie Grall-Bronnec, PH Nantes University Hospital
Principal Investigator: Régis Bouquié, AHU Nantes University Hospital
Principal Investigator: Stéphane Bézieau, Pr Nantes University Hospital
Principal Investigator: Pierre Bodenez University Hospital, Brest
Principal Investigator: Morgane Guillou-Landréat Morlaix Hospital
Principal Investigator: Bertrand Legeay Medico-psychological regional service nantes University Hospital
Principal Investigator: Isabelle Martineau La Métairie center care support and prevention of addiction
Principal Investigator: Philippe Levassor La Rose des Vents center care support and prevention of addiction
Principal Investigator: Jean-Yves Guillet General practitioners in the drug-addiction network of the Nantes Area
  More Information

Responsible Party: Nantes University Hospital Identifier: NCT01847729     History of Changes
Other Study ID Numbers: RC12_0498
Study First Received: April 10, 2013
Last Updated: March 24, 2016

Keywords provided by Nantes University Hospital:
pathological gambling
Opiate dependence
Opiate substitution treatment
Patients addicted to opiates
OST in place
cytochrome P450 2D6
Therapeutic Drug Monitoring

Additional relevant MeSH terms:
Substance-Related Disorders
Opioid-Related Disorders
Chemically-Induced Disorders
Mental Disorders processed this record on April 27, 2017